PLUS1
0.749
0.024 (3.31%)
0.024 (3.31%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aytu Bioscience Inc | AYTU | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.0647 | -8.19% | 0.725 | 0.7118 | 0.7821 | 0.78 | 0.7897 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.73 | 0.85 | 0.12 | 14.12% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 687 | 370,771 | $ 0.7479618 | $ 277,323 | 149,695 | 0.65 - 2.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:59:46 | formt | 400 | $ 0.749 | USD |
Aytu Bioscience Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 15.03M | 20.73M | $ -10.19M | -4.48 | - | 18.85M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 2.00 | 9.10% |
Aytu Bioscience News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/12/2019 | 06:07 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/07/2019 | 16:58 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) |
| 11/07/2019 | 16:20 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 11/04/2019 | 17:17 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) |
| 11/04/2019 | 09:06 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/04/2019 | 08:31 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting.. |
| 11/01/2019 | 17:16 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AYTU Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.713 | 0.95 | 0.70 | 0.7898839 | 400,186 | 0.012 | 1.68% |
| 1 Month | 0.869 | 0.95 | 0.66 | 0.777948 | 154,846 | -0.144 | -16.57% |
| 3 Months | 0.7593 | 1.10 | 0.65 | 0.8345798 | 151,824 | -0.0343 | -4.52% |
| 6 Months | 1.38 | 1.80 | 0.65 | 1.01 | 131,897 | -0.655 | -47.46% |
| 1 Year | 1.07 | 2.90 | 0.65 | 1.62 | 368,432 | -0.345 | -32.24% |
| 3 Years | 6.35 | 6.96 | 0.232963 | 0.8723713 | 780,892 | -5.63 | -88.58% |
| 5 Years | 6.35 | 6.96 | 0.232963 | 0.8723713 | 780,892 | -5.63 | -88.58% |
Aytu Bioscience Description
| Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company markets a portfolio of prescription products addressing large therapeutic markets. The primary care portfolio includes Natesto, the only FDA-approved nasal formulation of testosterone, ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, Cefaclor, Karbinal ER, and Poly-Vi-Flor and Tri-Vi-Flor. |
